68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations

Mexican women with ovarian cancer have a high prevalence of germline BRCA mutations. The most frequent alteration is the deletion exons 9 to 12 BRCA1 (BRCA1-Del Exon 9-12), which has been associated founder effect in this population. mutation long genomic rearrangement that could affect not only clinical features but also prognosis patients carrying alteration. This retrospective study evaluated characteristics and BRCA1/2 mutations after receiving first line treatment platinum-based chemotherapy between 2015 2022. aim was compare progression-free survival (PFS) other Patients treated front-line iPARP maintenance were excluded. Of 531 who tested for mutation, 181 positive (34.1%). Thirty-seven (20.4%) carriers 144 (79.6%) had One hundred fifty-seven included final analysis. median follow-up time 57 months. PFS 28.7 months, while 15.3 months (HR, 0.72; CI 95% 0.46 – 0.95; P= 0.05). Median overall reached 131 (HR 0.25; 0.0.88 P=0.01).Table: 68PSurvival analysisnMedian (CI 95%)PPFSTotal15717.28 (14.06 - 20.49)Mutation type0.05 mutation3228.74 (15.10 42.38) Other mutations12515.31 (12.59 18.02)BRCA type0.32 BRCA18414.91 (11.88 17.94) BRCA24116.75 (11.77 21.73) 42.38)OSTotal157137.46 (103.21 171.70)Mutation type0.010 mutation32NR (NR NR) mutations125131 (90.47 172.49)BRCA type0.013 BRCA184109.60 (65 154.20) BRCA241NR Open table new tab better compared